Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies

Mehrnoosh Khodaeian, Samaneh Enayati, Ozra Tabatabaei-Malazy, and Mahsa M. Amoli

1Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
2Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Ozra Tabatabaei-Malazy; tabatabaeiml@farabi.tums.ac.ir and Mahsa M. Amoli; amolimm@tums.ac.ir

Received 16 October 2014; Accepted 15 January 2015

Academic Editor: Aziz Ghahary

Copyright © 2015 Mehrnoosh Khodaeian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Diabetes mellitus as the most prevalent metabolic disease is a multifactorial disease which is influenced by environmental and genetic factors. In this systematic review, we assessed the association between genetic variants and diabetes/its complications in studies with Iranian populations.

Methods. Google Scholar, PubMed, Scopus, and Persian web databases were systematically searched up to January 2014. The search terms were "gene," "polymorphism," "diabetes," and "diabetic complications"; nephropathy, retinopathy, neuropathy, foot ulcer, and CAD (coronary artery diseases); and Persian equivalents. Animal studies, letters to editor, and invitro studies were excluded.

Results. Out of overall 3029 eligible articles, 88 articles were included. We found significant association between CTLA-4, IL-18, VDR, TAP2, IL-12, and CD4 genes and T1DM, HNFα and MODY, haptoglobin, paraoxonase, leptin, TCF7L2, calreticulin, ERα, PPAR-γ2, CXCL5, calpain-10, IRS-1 and 2, GSTM1, KCNJ11, eNOS, VDR, INSR, ACE, apoA-I, apo E, adiponectin, PTPN1, CETP, AT1R, resistin, MMP-3, BChE K, AT2R, SUMO4, IL-10, VEGF, MTHFR, and GSTM1 with T2DM or its complications.

Discussion. We found some controversial results due to heterogeneity in ethnicity and genetic background. We thought genomewide association studies on large number of samples will be helpful in identifying diabetes susceptible genes as an alternative to studying individual candidate genes in Iranian populations.

1. Introduction

Diabetes mellitus, as the most prevalent metabolic disorder, is characterized by chronic hyperglycemia due to defect in insulin secretion by beta cells of Langerhans islets or resistance against insulin action [1–3]. More than 300 million people are suffering from diabetes mellitus all over the world and studies show that population aging, changes in lifestyle and improvement in detection techniques are most important factors in increasing the numbers of cases [4]. The prevalence of type 2 diabetes mellitus (T2DM) varies in different populations from less than 6% in most populations to more than 50% in Pima Indians [5]. In 2013 it was reported that in Middle East region about 35 million people suffered from diabetes. The prevalence of diabetes has been estimated as 382 million people throughout the world while nearly 176 million of them seem to be still undiagnosed. It is predicted that this prevalence reaches to 592 million by 2035. Diabetes mellitus can also cause complications in most of organs: heart, eye, kidney, and nervous system which has resulted in high economic cost and burden [6]. Therefore, diagnosis of disease in early stages is very important.

A systematic review showed that between years 1996 and 2004 the prevalence of type 2 diabetes in Iran was 24% and the risk was 1.7% greater in women. According to this report the prevalence of T2DM in Iran seems to be
highest amongst developing countries. Previous reports on total urban population of Middle Eastern countries show the prevalence of T2DM as 3.4% in Sudan, 20% in United Arab Emirates, 8.5% in Bahrain, and 12.1% in India [7].

Diabetes Mellitus is categorized into the following groups.

Type 1 diabetes mellitus (T1DM) includes 5–10% of diabetic patients. Cellular-mediated autoimmune destruction of the beta-cells of the pancreas results in T1DM. It classically occurs in juveniles and affected patients are dependent on insulin injection in their lifetime and are very prone to ketosis [1, 8, 9].

T2DM includes 90–95% of patients with diabetes. Patients with type 2 diabetes may be asymptomatic for long period of time. Vascular complications such as nephropathy, neuropathy, retinopathy, and cardiovascular disease may develop in these patients. The impact of genetic component appears to be stronger in T2DM compared to T1DM [1, 8, 9].

Gestational diabetes mellitus (GDM) is another type which is observed during pregnancy and the prevalence may range from 1 to 14% in all pregnancies [1, 8, 9].

MODY (maturity onset diabetes of young) is monogenic form of diabetes comprised of several types with various features which is consisting of 1–5% of patients diagnosed as T2DM. The onset of this type of diabetes is normally before 25 years and its treatment is independent of insulin. MODY in its different forms is inherited in autosomal dominant pattern and presents as a result of mutation in transcription factors genes including HNF4α (hepatocyte nuclear factor), HNF1β, IPF1 (insulin promoter factor), and neuro-DI [1, 8, 9].

There are also other types of diabetes which are considered as secondary to other conditions, for example, any damage to pancreas such as removal of pancreatic tissue, trauma, pancreatic carcinoma, and infection, or underlying diseases including endocrine diseases that alter different hormones secretion which are antagonist to insulin resulting in various clinical manifestations such as acromegaly, Cushing’s syndrome, pheochromocytoma, glucagonoma, somatostatinoma, and diabetes. Diabetes (or carbohydrate intolerance) is also found in increased frequency with a large number of genetic syndromes such as Wolfram syndrome, which causes diabetes mellitus, diabetes insipidus, and other neurodegenerative disorders, MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke) which is presented with myopathy and encephalopathy caused by mitochondrial mutation, MIDD (maternally inherited diabetes and deafness) which causes diabetes, and IPEX (immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome) which is X-linked and alters immune system and causes multiple endocrine problems [1, 8, 9].

Diabetes mellitus is a multifactorial disease with both environmental and genetic causes affecting its presence and incidence. Genome wide association studies revealed the genetic heterogeneity of diabetes and the fact that difference in ethnicity can result in different susceptible genes associated with diabetes [10, 11]. Studies on candidate genes related to diabetes revealed that several genes including PPARγ (peroxisome proliferator-activates receptor gamma), IRS1 and 2 (insulin receptor substrate), KCNJ11 (potassium inwardly rectifying channel), and HNFA are associated with T2DM. Genome wide association studies (GWAS) showed that many genes including Calpain 10 and TC7P2 (transcription factor 7-like 2) are associated with T2DM. HHEX (hematoepitically expressed homebox), SLC30A8 (solute carrier family 30 (zinc transporter), member 8), CDK2A/B (cyclin-dependent kinase inhibitor 2A/B), and I2G2BP2 (insulin-like growth factor 2) are other genes which have been shown to be associated with T2DM based on GWAS. Some of these genes are expressed in beta cells or involved in insulin secretion pathways [12, 13]. Other candidate genes in association with T2DM include PPARγ, ACE (angiotensin converting enzyme), MTHFR (methylene tetrahydrofolate reductase), FABP2 (fatty acid binding protein-2), and FTO (fat mass and obesity associated gene) [14]. GWAS was carried out in many populations including Finnish, French, and American Caucasians and showed different loci on most of the chromosomes associated with T2DM [15]. Systematic review and meta-analysis studies also confirmed the association of some genes such as PGC-1α (peroxisome proliferator-activates receptor gamma coactivator-1α) and adiponectin with T2DM [16, 17]. The genetic loci associated with T1DM have also been examined. For example, insulin (INS) gene VNTRs (variable number of tandem repeats) with a protective effect is a variants related to T1DM. In addition PTEN (protein tyrosin phosphatase), CTLA4, and IL2RA genes have also been shown as candidates for T1DM due to their role in T-cell signaling. Studies have also confirmed the association between IFIHI, CYP27BI, and CLEC16, which are important in immune system and T1DM [18].

There is no inclusive information for genetic association studies of diabetes in Middle Eastern population including Iranian population. In order to make a comprehensive approach, we aimed to collectively investigate and gather data for association between genetic variants and type 2 diabetes in Iranian population in a systematic review study.

2. Research Design and Methods

This study is reported according to PRISMA (preferred reporting items for systematic reviews and meta-analyses) guideline [19].

2.1. Data Sources and Searches. We systematically searched international web databases: Google Scholar, PubMed, Scopus, and Persian web databases; IranMedex; and Magiran to investigate the association of genetic variants with diabetes and its complications in Iranian population up to January 2014. The search terms were “gene,” “polymorphism,” “diabetes,” “diabetes’ complications,” nephropathy, retinopathy, neuropathy, foot ulcer, and CAD (coronary artery disease) and their MeSH terms and Persian equivalents with diabetes. At least three emails were sent to the corresponding author of articles which were not accessible as full text or had insufficient data. Duplicate articles and multiple publications from the same population were excluded and the most relevant data were used for the investigation. The references of all selected articles were investigated.

2.2. Study Selection. We included all observational population-based studies ≥100 sample size, which were conducted
as case-control, cohort, or cross sectional. According to WHO criteria, diabetes mellitus was defined as FBS ≥ 7 mmol/L (126 mg/dL) or 2 h plasma glucose ≥11.1 mmol/L (200 mg/dL) [20]. In addition, we excluded animal studies, clinical trials, short communications, letters to editor, dissertations, in vitro studies, review articles, and population-based studies conducted in pregnant women. Two researchers, SE and MKH, independently reviewed title, abstract, and full text of each article to assess the eligible articles according to inclusion and exclusion criteria. Inclusion and exclusion of articles were supervised by a third reviewer (OTM) in case of conflicts. There was no limitation for language.

2.3. Data Extraction and Quality Assessment. The following data were extracted and presented in an excel sheet: author(s), year, genes and SNPs, patients’ characteristics (sample size, age, and sex), city, study design, genotyping method, and significant association. Six selected items from the STROBE (strengthening the reporting of observational studies in epidemiology) checklist [21] was used for quality assessment of the included studies and assessed separately for each included article. The below items were considered: (a) clearly define the outcome and association between gene variants and diabetes; (b) give the eligibility criteria; (c) present key elements of study design; (d) report numbers or significance/nonsignificance statistically of outcome events; (e) give characteristics of study participants; and (f) describe the locations and relevant dates. All studies with quality score ≥3 were considered as high quality study and included in our systematic review.

2.4. Data Synthesis and Analysis. Due to heterogeneity in genotyping techniques and also differences in genetic variants studied in assessed included articles performing a meta-analysis was impossible.

3. Results

3.1. Search Results. A summary of the literature review process performed in this study is presented in a flow chart in Figure 1. In final step 88 eligible studies were included in this study and assessed due to the inclusion/exclusion criteria [22–109]. Table 1 shows the summary of each included investigation.

3.2. Studies Characteristics. Overall 27,396 diabetics and healthy subjects were studied in this systematic review. All of the subjects were recruited from total urban population. T2DM was the most investigated type of diabetes (42 studies) [22–75]. Among diabetes complications, diabetic nephropathy and CAD were the most examined, respectively [80–105]. Twelve studies were carried out on T1DM [22–33]. The least investigated complication was diabetic foot ulcer which was assessed only in one study [109]. Retinopathy and insulin resistance were also among the least investigated complications including 3 and 4 studies, respectively [76–79, 106–108]. Only one study assessed MODY in our review [34]. All of the studies were performed on both genders except for one which was performed on males [45].

Details of the included studies are described as below.
| Reference                     | Genes/SNP or allele                  | Patients’ characteristics | City       | Study design | Method       | Significant association                                                                 |
|-------------------------------|--------------------------------------|---------------------------|------------|--------------|-------------|----------------------------------------------------------------------------------------|
| Ahmadi et al., 2013 [22]      | CTLA-4+/49A/G                         | 60 T1DM, 56 T2DM, and 107 healthy, male (M)/female (F) | Kurdistan  | Case control | PCR-RFLP    | Positive significant association between AG carriers and T1DM (P = 0.01)                 |
| Karamizadeh et al., 2013 [23] | (i) Osteopontin/rs1226772 (ii) Integrin α4/rs444263 CD44/rs893 | 87 T1DM and 86 healthy, <20 yr, M/F | Shiraz     | Case control | PCR-RFLP    | Nonsignificance                                                                        |
| Rahbani-Nabar et al., 2013 [24]| IL-18/−137C/G                        | 104 T1DM and 92 healthy, 9–32 yr, M/F | Tabriz     | Case control | SS-PCR      | Positive significant association between GG carriers and T1DM (P = 0.037)                |
| Bonakdaran et al., 2012 [25]  | (i) VDR/FokI (FF, Ff, ff), (ii) BsmI (BB, Bb, bb), Apal (AA, Aa, aa), (iii) TaqI (TT, Tt, tt) | 69 T1DM and 45 healthy, <35 yr, M/F | Mashhad    | Case control | PCR-RFLP    | Positive significant association between AA (P = 0.003), FF (P = 0.008), and Bb (P = 0.014) carriers with T1DM, significant association between ff genotype and history of ketoacidosis (P = 0.04) |
| Mohammadnejad et al., 2012 [26]| (i) VDR/TaqI (TT, Tt, tt) (ii) VDR, FokI, BsmI, Apal | 87 T1DM and 100 healthy, 17–38 yr, M/F | Mashhad    | Case control | PCR-RFLP    | (i) Negative significant association between TT carriers and T1DM (P = 0.007)           |
| Afshari et al., 2011 [27]     | (i) TAP2/Ile379Val (ii) TAP2/Stop687Gln (iii) TAP2/Ala565Thr, Arg651Cys, Ala665Thr | 87 T1DM and 104 healthy, <30 yr, M/F | Mashhad    | Case control | ARMS-PCR     | (i) Significant association between Ile379Val and T1DM (P = 0.001)                       |
| Massoud et al., 2009 [28]     | (i) IL-18/−137C/G (ii) IL-18/−607A/C | 75 T1DM and 88 healthy, <30 yr, M/F | Tehran     | Case control | PCR-SSP     | (i) Positive significant association between GG carriers and T1DM (P = 0.0001)          |
|                               |                                      |                           |            |              |             | (ii) Significant association between CC genotype with T1DM (P = 0.0001)                  |
|                               |                                      |                           |            |              |             | (iii) Nonsignificance association between other carriers of IL-18 and T1DM              |
| Reference            | Genes/SNP or allele | Patients' characteristics | City          | Study design | Method       | Significant association                                                                 |
|----------------------|---------------------|---------------------------|---------------|--------------|-------------|--------------------------------------------------------------------------------------------|
| Masoud et al., 2007 [29] | TGFβ1+/915C/G       | 75 T1DM and 88 healthy, <30 yr, M/F | Tehran        | Case control | PCR-SSP     | Nonsignificance                                                                            |
| Masoud et al., 2007 [30] | IL-12+1188A/C       | 75 T1DM and 88 healthy, <30 yr, M/F | Tehran        | Case control | PCR-SSP     | Significant association between AA and AC genotype and T1DM (P = 0.035)                   |
| Mojtahedi et al., 2006 [31] | IL-18−607A/C, −137C/G | 112 T1DM and 194 non-DM, <15 and >15 yr, M/F | Shiraz        | Case control | PCR-SSP     | Significant association with T1DM in onset >15 yr (P = 0.027) (i) Positive significant association between AG carriers and T1DM (P = 0.00) (ii) Negative significant association between AA carriers and T1DM (P = 0.00) Negative significant association between A3 allele and T1DM (P = 0.025) Positive significant association between A5 allele and T1DM (P = 0.001) |
| Mojtahedi et al., 2005 [32] | CTLA-4+/49A/G       | 109 T1DM and 331 healthy, 0–37 yr, M/F | Shiraz        | Case control | PCR-RFLP    | Positive significant association of Cys/Cys and negative significant association of Ser/Ser carriers with T2DM (P < 0.05) |
| Zamani et al., 2005 [33] | CD4/A2-A9           | 92 T1DM and 108 healthy, >35 yr, M/F | Tehran        | Case control | PCR         | The mutation was found in patients and relatives but not in controls                      |
| Taghavi et al., 2009 [34] | HNFα/Val255Met      | 30 MODY, 21 relatives, and 50 healthy, 25–35 yr, M/F | Mashhad       | Case control | PCR-FLP sequencing |                                                                                           |
| Ahmadi et al., 2013 [22] | CTLA-4+/49A/G       | Said above T2DM with MVCs, 134 T2DM with MVCs, 71 T2DM without MVCs, 46–72 yr, M/F | Said above    | Said above   | Said above   | Nonsignificance                                                                            |
| Amiri et al., 2013 [35] | Haptoglobin/1-1, 2-1, 2-2 | 71 T2DM without MVCs, 45–72 yr, M/F | Sari          | Case control | PCR         | Hp2-2 highly significant for T2DM (P = 0.05)                                               |
| Andalib et al., 2013 [36] | Paraoxonase 2/Ser311Cys | 100 T2DM and 100 healthy, 51 yr, M/F | Isfahan       | Case control | PCR-RFLP    | Positive significant association of Cys/Cys and negative significant association of Ser/Ser carriers with T2DM (P < 0.05) |
| Kohan et al., 2013 [37] | Leptin/G-2548A      | 100 T2DM and 100 healthy, 44–66 yr, M/F | Arsanjan      | Case control | PCR-RFLP    | Positive significant association between GG carriers and T2DM (P = 0.004)                  |
| Alami et al., 2013 [38] | TCF7L2/rs7903146 (C/T) | 233 T2DM and 233 controls, >40 yr, M/F | Gorgan        | Case control | PCR-RFLP    | CC and CT genotypes significant difference between T2DM and controls (P = 0.045)         |
| Mahmazi et al., 2013 [39] | Calreticulin        | 120 T2DM and 530 controls, 43–66 yr, M/F | Zanjan        | Case control | PCR-SCA     | The 9 bp deletion of 397–399 codons G>T mutation at IVSII-142 in T2DM not in controls     |
| Reference                  | Genes/SNP or allele          | Patients' characteristics | City            | Study design | Method         | Significant association                                                                 |
|---------------------------|------------------------------|---------------------------|-----------------|--------------|----------------|------------------------------------------------------------------------------------------|
| Mohammadi et al., 2013 [40] | (i) ERα/PvuII (PP, Pp, pp)   | 174 T2DM and 174 ND,      | Jahrom          | Case control | PCR-RFLP       | (i) Significant association with T2DM ($P = 0.014$), TC ($P = 0.007$), and TG ($P = 0.005$) female carriers 
(ii) Significant association with T2DM ($P = 0.002$), TC ($P = 0.003$), and TG ($P = 0.009$) female carriers  |
|                           | (ii) ERα/XbaI (XX, Xx, xx)  | 35–65 yr, M/F             |                 |              |                | Negative significant association between Ala/Ala carriers ($P < 0.001$) and positive significant association between Ala/Pro carriers with T2DM ($P < 0.001$) |
| Motavallian et al., 2013 [41] | PPAR-γ2/Pro12Ala           | 100 T2DM and 100 healthy, | Isfahan         | Case control | PCR-RFLP       | Nonsignificance                                                                           |
|                           |                             | 51 yr, M/F                |                 |              |                | Positive significant association of GC carriers ($P = 0.006$) and negative significant association of GG carriers with T2DM ($P = 0.01$) |
| Sepah et al., 2013 [42]   | HNF-1α/Ala98Val,            | 100 T2DM and 50 healthy   | Mashhad         | Case control | PCR-RFLP       | Nonsignificance                                                                           |
|                           | GLP-1R/Thr149Met,           | controls, ≤35 and >35 yr, |                 |              |                | Gall as risk factor of T2DM ($P = 0.037$)                                                  |
| Sheikhha et al., 2013 [43] | APOA1/MSP-I                | 200 T2DM and 200 healthy, | Yazd            | Case control | PCR-RFLP       | Nonsignificance                                                                           |
|                           |                             | 41.8 yr, M/F              |                 |              |                | (i) Positive significant association of GR ($P = 0.001$) and RR ($P = 0.0001$) carriers with T2DM  |
| Yaghoubi et al., 2013 [44] | CXCL5/−156G > C            | 100 T2DM, 54 yr and 100   | Ardabil         | Case control | PCR-RFLP       | (ii) Positive significant association between GD carriers and T2DM ($P = 0.016$)              |
|                           |                              | healthy, 56 yr, M/F       |                 |              |                | Positive significant association between T1' carriers and T2DM ($P = 0.014$)                |
| Bahreini et al., 2012 [45] | Calpain-10/SNP43(A/G)      | 102 T2DM and 100 healthy, | East Azerbayjan | Case control | PCR-RFLP       | (i) Positive significant association of pooled Pp + pp male carriers ($P = 0.001$) with T2DM  |
|                           |                              | 40–70 yr, M               |                 |              |                | (ii) Positive significant association of pooled XX+xx male carriers ($P = 0.026$) with T2DM  |
| Derakhshan et al., 2012 [46] | SDF-1β/G801A               | 200 T2DM and 200 healthy, | Rafsanjan       | Case control | PCR-RFLP       |                                                                                          |
| Haghani et al., 2012 [47]  | (i) IRS-1/G972R            | 336 T2DM and 341 healthy, | Ilam and        | Case control | PCR-RFLP       |                                                                                          |
|                           | (ii) IRS-2/G1057D          | 44–63 yr, M/F             | Kermanshah     |              |                | (ii) Positive significant association between GD carriers and T2DM ($P = 0.016$)              |
| Alami et al., 2012 [48]   | TCF7L2/rs12255372 (G/T)    | 236 T2DM and 255 healthy, | Gorgan          | Case control | PCR-RFLP       | Positive significant association between T1' carriers and T2DM ($P = 0.014$)                |
|                           |                              | >37 yr, M/F               |                 |              |                | (i) Positive significant association of pooled Pp + pp male carriers ($P = 0.001$) with T2DM  |
| Meshkani et al., 2012 [49] | (i) ERα/PvuII (PP, Pp, pp) | 155 T2DM and 377 controls,| Tehran          | Case control | PCR-RFLP       | (ii) Positive significant association of pooled XX+xx male carriers ($P = 0.026$) with T2DM  |
|                           | (ii) ERα/XbaI (XX, Xx, xx) | 23–79 yr, M/F             |                 |              |                |                                                                                          |
| Reference                        | Genes/SNP or allele          | Patients’ characteristics | City       | Study design | Method      | Significant association                                                                 |
|---------------------------------|------------------------------|---------------------------|------------|--------------|-------------|----------------------------------------------------------------------------------------|
| Moasser et al., 2012 [50]       | GSTM1/present/null           | 171 T2DM and 169 healthy, | Shiraz     | Case control | PCR-RFLP   | GSTM1-null \((P = 0.016)\) and interaction of GSTM-null/GSTT1-null \((P = 0.022)\) significant association with T2DM |
|                                 | GSTT1/present/null           | 25–65 yr, M/F             |            |              |             |                                                                                        |
|                                 | GSTP1/Ile105Val              |                           |            |              |             |                                                                                        |
| Mohaddes et al., 2012 [51]      | SLC20A8/Arg325Trp            | 125 T2DM and 125 controls,| Azarbayan  | Case control | PCR-RFLP   | Nonsignificance                                                                        |
| Oladi et al., 2012 [52]         | Glucokinase/−30G/A           | 542 subjects, 18–65 yr, M/F| Mashhad    | Cross sectional | PCR-RFLP | Positive significant association between TT carriers and T2DM \((P = 0.008)\)          |
| Palizban et al., 2012 [53]      | TCF7L2/rs7903146 (C/T)       | 110 T2DM and 80 healthy,  | Isfahan    | Case control | PCR-RFLP   |                                                                                        |
|                                 | 46–67 yr, M/F                |                           |            |              |             |                                                                                        |
| Tabatabaei-Malazy et al., 2012  | ApoE/E3-E3, E2-E3, E4-E3     | 156 T2DM and 155 healthy, | Tehran     | Case control | PCR-RFLP   | Positive significant association between KK carriers and obese T2DM \((P = 0.037)\)     |
| [54]                            |                              | 25–65, M/F                |            |              |             |                                                                                        |
| Ghasemi et al., 2012 [55]       | KCNJ11/E23K                  | 358 T2DM and 388 healthy, | Rasht      | Case control | Real time PCR |                                                                                        |
|                                 | 41–69 yr, M/F                |                           |            |              |             |                                                                                        |
| Ranjbar et al., 2011 [56]       | Adiponectin/+45T/G,−1139G/A  | 244 T2DM and 99 healthy,  | Rafsanjan  | Case control | PCR-RFLP   | Nonsignificant                                                                        |
|                                 | 37–65 yr, M/F                |                           |            |              |             |                                                                                        |
| Mehrab-Mohseni et al., 2011     | eNOS VNTR/intron 4 a/b       | 220 T2DM and 96 healthy,  | Rafsanjan  | Case control | PCR         | Positive significant association between aa or ab carriers and T2DM \((P = 0.02)\)     |
| [57]                            |                              | 53 ± 15 yr, M/F           |            |              |             |                                                                                        |
| Nosratabadi et al., 2011 [58]   | (i) VDR/TaqI (TT/TT/tt)      | 100 T2DM and 100 healthy, | Rafsanjan  | Case control | PCR-RFLP   | (i) Positive significant association between Tt carriers and T2DM \((P < 0.001)\)       |
|                                 | (ii) VDR/ApaI (AA/Aa/aa)     | 40 yr, M/F                |            |              |             | (ii) Nonsignificant association between ApaI carriers and T2DM                           |
|                                 |                              |                           |            |              |             |                                                                                        |
| Saberi et al., 2011 [59]        | ENPP1/K121Q                  | 155 T2DM and 377 healthy, | Tehran     | Case control | PCR-RFLP   | Nonsignificance                                                                        |
|                                 | 23–79 yr, M/F                |                           |            |              |             |                                                                                        |
| Fallah et al., 2010 [60]        | SUMO4/Met55Val (163A/G)      | 50 T2DM and 50 healthy,   | Tehran     | Case control | PCR-RFLP   | Nonsignificance                                                                        |
|                                 | 25–45 yr, M/F                |                           |            |              |             |                                                                                        |
| Heidari et al., 2010 [61]       | UCP2/−866G/A                 | 75 T2DM, 75 ND obese and 75| Tehran     | Case control | PCR-RFLP   | Nonsignificance                                                                        |
|                                 | ND nonobese, 35–76 yr, M/F   |                           |            |              |             |                                                                                        |
| Nazem et al., 2010 [62]         | 5HTTLPR/SS, SL, LL           | 90 T2DM and 90 healthy,   | Shiraz     | Case control | PCR         | Nonsignificance                                                                        |
|                                 | 54–66 yr, M/F                |                           |            |              |             |                                                                                        |
| Bazzaz et al., 2010 [63]        | MTHFR/C677T                  | 401 T2DM, 74 ND obese and 207| Tehran     | Case control | PCR-RFLP   | Nonsignificance                                                                        |
|                                 | ND nonobese, 30–63 yr, M/F   |                           |            |              |             |                                                                                        |
| Emamgholipour et al., 2009 [64] | resistin/−420C/G             | 47 T2DM and 66 healthy,   | Tehran     | Case control | PCR-RFLP   | Positive significant association between CC carriers and T2DM \((P = 0.009)\)          |
|                                 | 58 ± 9 yr, M/F               |                           |            |              |             |                                                                                        |
| Hasani-Ranjbar et al., 2009 [65]| CXCL5/−156G/C                | 230 T2DM and 120 healthy, | Rafsanjan  | Case control | PCR-RFLP   | Positive significant association between GC or CC carriers and T2DM \((P = 0.004)\)     |
|                                 | 40–63 yr, M/F                |                           |            |              |             |                                                                                        |
| Reference                          | Genes/SNP or allele | Patients’ characteristics | City       | Study design | Method                  | Significant association |
|-----------------------------------|---------------------|---------------------------|------------|--------------|-------------------------|------------------------|
| Kazemi Arababadi et al., 2009 [66]| IL-4/−590C/T IFN-γ/+874T/A | 160 T2DM and 160 healthy, 38 ± 9 yr, M/F | Rafsanjan | Case control | PCR-RFLP ARMS-PCR       | Nonsignificance        |
| Arababadi et al., 2009 [67]      | CCR5/Δ32mutation     | 200 T2DM and 300 healthy, 40 ± 9 yr, M/F | Rafsanjan | Case control | Gap-PCR                 | Nonsignificance        |
| Kazemi et al., 2009 [68]         | INSR                | 128 T2DM, >40 yr, M/F     | Tehran     | Case control | PCR CSGE sequencing     | Following mutations were found only in T2DM S111>C, S147>T, G566, and 628T>A on exon 2 694G>C and 680G>A on exon 3 1627A>T on exon 8 AT> TG on intron 9 2007C>C/T on exon 9 2595C>G/T and 2669G>C/G on exon 13 2706 and 2717>C, 2752C>T, 2753C>G, on exon 14 3471T>A and 3516T>G on exon 19 |
| Mirzaei et al., 2009 [69]        | PPARγ2/Pro12Ala     | 78 normal, 78 obese, 78 T2DM, and 78 obese T2DM, 25–64 yr, M/F | Tehran     | Cross sectional | PCR-RFLP               | Nonsignificance        |
| Nikzamir et al., 2008 [70]       | ACE/insertion (I)/deletion (D) | 170 T2DM and 144 healthy, M/F | Tehran     | Case control | PCR                     | Positive significant association between DD carriers and T2DM ($P = 0.02$) |
| Sharifi et al., 2008 [71]        | HFE/H63D, C282Y     | 101 T2DM and 101 healthy, 55 ± 11 yr, M/F | Zanjan     | Case control | PCR                     | Nonsignificance        |
| Besharat et al., 2007 [72]       | (i) ApoA-I/G-75A (ii) ApoA-I/C+83T | 215 subjects, 26–64 yr, M/F | Tehran     | Cross sectional | PCR-RFLP               | (i) Nonsignificant association between G-75A carriers and T2DM (ii) Positive significant association between CT carriers and T2DM ($P = 0.028$) |
| Hasani-Ranjbar et al., 2007 [73] | Adiponectin/+45T/G   | 80 T2DM obese, 72 T2DM nonobese, and 70 healthy, 25–64 yr, M/F | Tehran     | Case control | PCR-RFLP               | Positive significant association between TT carriers and nonobese T2DM ($P = 0.04$) |
| Meshkani et al., 2007 [74]       | PTPN1/−51delA, −451A>G, −467T>C, −1023C>A, −1045G>A, −1286 3 bp del ACA, −1291 9 bp del CTAGACTAA | 174 T2DM and 412 healthy, 23–79, M/F | Tehran     | Case control | PCR sequencing PCR-RFLP | Nonsignificance        |
| Meshkani et al., 2007 [75]       | PPARγ1/Pro12Ala     | 412 T2DM and 284 healthy, 23–79 yr, M/F | Tehran     | Case control | PCR-RFLP               | Negative significant association between Pro/Ala or Ala/Ala carriers and T2DM ($P = 0.003$) |
| Reference | Genes/SNP or allele | Patients' characteristics | City | Study design | Method | Significant association |
|-----------|--------------------|--------------------------|------|--------------|--------|-------------------------|
| Namvaran et al., 2012 [76] | (i) Adiponectin+/45T/G (ii) Adiponectin receptor-2+/795G/A | 101 T2DM and 128 healthy, 30–70 yr, M/F | Shiraz | Case control | PCR-RFLP | (i) Positive significant association between TG carriers and T2DM ($P = 0.032$) (ii) Non-significant association between +794G/A carriers and insulin resistance |
| Namvaran et al., 2011 [77] | PPARγ/Pro12Ala | 101 T2DM and 128 healthy, 30–70 yr, M/F | Shiraz | Case control | Real-time PCR | Positive significant association between Ala allele carriers and T2DM ($P = 0.036$) |
| Hossein-nezhad et al., 2009 [78] | VDR/FokI (FF, Ff, ff) | 105 T2DM, 55 ± 10 yr, M/F | Tehran | Case series | PCR-RFLP | Positive significant association between ff carriers and insulin resistance index ($P = 0.02$) Negative significant association between H8insG carriers and insulin resistance index ($P = 0.041$) |
| Moosapoor et al., 2007 [79] | PTPN1/148insG | 71 T2DM and 264 ND, 20–80 yr, M/F | Tehran | Case control | PCR-RFLP | (i) Nonsignificant association between 148insG carriers and insulin resistance index ($P = 0.041$) |
| Bayatmakoo et al., 2013 [80] | Paraoxonase 1/163T/A (L55M) | 105 CAD/DM and 95 CAD/ND, <85 yr, M/F | Tabriz | Case control | PCR-RFLP | Positive significant association between RR carriers and CAD/DM ($P < 0.05$) |
| Bayatmakoo et al., 2012 [81] | Paraoxonase 1/575G>A (Q192R) | 105 DM/CAD and 95 CAD/ND, <85 yr, M/F | Tabriz | Case control | PCR-RFLP | (i) Negative significant association between 45TT carriers and CAD ($P = 0.033$) | (ii) Positive significant association between 276GG carriers and CAD ($P = 0.023$) |
| Esteghamati et al., 2012 [82] | (i) Adiponectin+/45T/G (ii) Adiponectin+/276G/T | 114 CAD/DM and 127 DM, 42–71 yr, M/F | Tehran | Case control | PCR-RFLP | (i) Nonsignificant association between 45TT carriers and CAD ($P = 0.033$) (ii) Positive significant association between 276GG carriers and CAD ($P = 0.023$) |
| Rahimi et al., 2012 [83] | eNOS/G894T CETP/B1 | 102 CAD/DM, 105 CAD/ND, 101 DM, and 92 ND, 45–66 yr, M/F | Kermanshah | Case control | PCR-RFLP | Positive significant association of concomitant presence of NOS3 T allele and CETP Bl allele with T2DM ($P = 0.004$) and CAD ($P = 0.002$) |
| Assali et al., 2011 [84] | ATIR/AI166C | 145 CAD/DM and 164 CAD, <50 and ≥50 yr, M/F | Mashhad | Case control | PCR-RFLP | Positive significant association of AC and CC carriers with DM ($P = 0.01$) |
| Emamgholi et al., 2009 [85] | Resistin−/−420C/G | 113 CAD with and without DM, 58 ± 9 yr, M/F | Tehran | Cross-sectional | PCR-RFLP | Positive significant association between CC carriers and DM ($P = 0.009$) |
Table 1: Continued.

| Reference                          | Genes/SNP or allele | Patients' characteristics | City     | Study design | Method       | Significant association                                                                 |
|-----------------------------------|--------------------|---------------------------|----------|--------------|--------------|----------------------------------------------------------------------------------------|
| Fallah et al., 2010 [86]          | MMP-3/−1612 5A/6A   | 305 CAD/DM and 313 DM, 61±9 yr, M/F | Tehran   | Case control | PCR-RFLP     | Positive significant association between 6A/6A carriers and CAS (P = 0.008)               |
|                                   |                    |                           |          |              |              | Positive significant association of GA, AA, and E4 carriers with CAD and DM (P < 0.05)   |
|                                   |                    |                           |          |              |              | Positive significant association of BChE K/ApoE4 carriers with CAD and DM (P < 0.05)    |
|                                   |                    |                           |          |              |              | Significant association of BChE K/ApoE4 with lipid profile (P < 0.05)                  |
| Vaisi-Raygani et al., 2010 [87]   | BChE K/G1615A APO E/E2, E3, E4 | 118 DM, 162 CAD/ND, 172 DM/CAD, and 179 healthy, 42–68 yr, M/F | Kermanshah | Case control | PCR-RFLP     | Positive significant association of GA, AA, and E4 carriers with CAD and DM (P < 0.05)   |
|                                   |                    |                           |          |              |              | Positive significant association of BChE K/ApoE4 carriers with CAD and DM (P < 0.05)    |
|                                   |                    |                           |          |              |              | Significant association of BChE K/ApoE4 with lipid profile (P < 0.05)                  |
| Rahimi et al., 2009 [88]          | Factor V Leiden/G1691A Prothrombin/G20210A MTHFR/C677T | 65 CAD/DM, 52 CAD/ND, and 59 healthy, 46064 yr, M/F | Kermanshah | Case control | PCR-RFLP     | Nonsignificance                                                                       |
| Nakhjavani et al., 2007 [89]      | ACE/I/D            | 82 DM with hypertension and 87 DM without hypertension, 49–63 yr, M/F | Tehran   | Case control | PCR           | Positive significant association between DD carriers and hypertension (P = 0.026)         |
| Vaisi-Raygani et al., 2007 [90]   | Apolipoprotein/E2, E3, E4 | 152 CAD/DM, 262 CAD/ND, and 300 healthy, 35–73 yr, M/F | Kermanshah | Case control | PCR-RFLP     | Positive significant association of E2 and E4 allele carriers with CAD (P < 0.001)       |
| Raffsanjan et al., 2013 [91]      | eNOS/4a/b, G894T    | 63 T2DM/microalbuminuria, 57 T2DM/macroalbuminuria, 52T2DM/normoalbuminuria, 121 DN, 101 healthy, 45–66 yr, M/F | Kermanshah | Case control | PCR-RFLP     | Positive significant association of 4a or 894T allele carriers and macro- (P = 0.01) or microalbuminuria (P = 0.02) |
| Rahimi et al., 2013 [92]          | AT2R/−1332G/A       | 28T2DM/microalbuminuria, 22T2DM/macroalbuminuria, 20T2DM/normoalbuminuria, and 112 healthy, 43–63 yr, M/F | Kermanshah | Case control | PCR-RFLP     | Positive significant association between AA carriers and nephropathy (P = 0.016)         |
| Shahsavari et al., 2013 [93]     | SUMO4/163A/G (M55V) | 50 T2D/DN and 50 T2DM non-DN, 25–45 yr, M/F | Tehran   | Case control | PCR-RFLP     | Positive significant association between AA carriers and nephropathy (P < 0.05)          |
| Arababadi et al., 2012 [94]      | IL-10/−592C/A       | 100 T2DM/non-DN, 100 T2DM/DN and 100 healthy, 31–49 yr, M/F | Rafsanjan | Case control | PCR-RFLP     | Positive significant association between CC carriers and DN (P = 0.001)                   |
Table 1: Continued.

| Reference          | Genes/SNP or allele | Patients’ characteristics                                                                 | City     | Study design | Method   | Significant association                                                                                                                                 |
|--------------------|---------------------|--------------------------------------------------------------------------------------------|----------|--------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Nikzamir et al., 2012 [95] | VEGF+/+405G/C | 255T2DM/microalbuminuria and 235T2DM/nonalbuminuric, 50–67 yr, M/F | Tehran   | Case control | PCR-RFLP | Positive significant association between GG carriers and albuminuria ($P = 0.002$)                                                                       |
| Rahimi et al., 2012 [96]   | MTHFR/A1298C, C677T ACE/I/D | 72T2DM/MicAlb, 68T2DM/MacAlb and 72 T2DM/non-DN, 46–65 yr, M/F | Kermanshah | Case control | PCR-RFLP | Positive significant association of ACE D/677T ($P = 0.053$) and ACE D/1298C ($P = 0.012$) carriers with macroalbuminuria                                           |
| Rahimi et al., 2012 [97]   | eNOS/G894T ACE/I/D | 72T2DM/microalbuminuria, 68T2DM/macroalbuminuria and 72 T2DM/non-DN, 46–65 yr, M/F | Kermanshah | Case control | PCR-RFLP | Positive significant association between ACE D carriers and macroalbuminuria ($P = 0.035$)                                                          |
| Felehgari et al., 2011 [98] | ACE/I/D | 72T2DM/microalbuminuria, 68T2DM/macroalbuminuria, 46–65 yr, M/F | Kermanshah | Case control | PCR      | Nonsignificance                                                                                                                                          |
| Jafari et al., 2011 [99]   | eNOS/G894T MTHFR/C677T, A1298C | 72T2DM/microalbuminuria, 68T2DM/macroalbuminuria and 72 T2DM/non-DN, 46–65 yr, M/F | Kermanshah | Case control | PCR-RFLP | (i) Positive significant association of eNOS T/A1298 C and eNOS T/677 T carriers with macroalbuminuria ($P < 0.05$) | (ii) Significant association of eNOS GT+TT carriers with lipid profile ($P < 0.05$) |
| Rahimi et al., 2011 [100]  | ACE/I/D Factor V Leiden/G1691A | 217/mean 55/both | Kermanshah | Case control | PCR-RFLP | Positive significant association between CT carriers and DN ($P < 0.001$)                                                                           |
| Arababadi, 2010 [101]     | IL-4−590C/T | 100 T2DM/DN and 150 healthy, 33–47 yr, M/F | Rafsanjan | Case control | PCR      | Nonsignificance                                                                                                                                          |
| Nosratabadi et al., 2010 [102] | (i) VDR/TaqI (TT/Tt/tt) (ii) VDR/ApaI (AA/Aa/aa) | 100 T2DM/non-DN, 100 T2DM/DN, and 100 healthy, 31–49 yr, M/F | Rafsanjan | Case control | PCR-RFLP | (i) Positive significant association between Tt carriers and DN ($P = 0.012$)                                                                         |
|                         |                 |                                                                                             |          |              |          | (ii) Nonsignificant association between ApaI carriers and DN                                                                                          |
|                         |                 |                                                                                             |          |              |          | (i) Positive significant association of 677T, 1298C and 677T/1298C carriers with macroalbuminuria ($P < 0.001$)                                |
| Rahimi et al., 2010 [103]  | MTHFR/C677T, A1298C | 72T2DM/microalbuminuria, 68T2DM/macroalbuminuria, and 72 T2DM/non-DN, 46–65 yr, M/F | Kermanshah | Case control | PCR-RFLP | (ii) Positive significant association of CT+TT and 677T/1298C carriers with microalbuminuria ($P < 0.001$)                                    |
| Reference | Genes/SNP or allele | Patients' characteristics | City | Study design | Method | Significant association |
|-----------|---------------------|--------------------------|------|--------------|--------|-------------------------|
| Nikzamir et al., 2009 [104] | ACE/I/D | 129 T2DM/microalbuminuria, 48T2DM/macroalbuminuria, and 145T2DM/normoalbuminuria, 59.4 ± 8.5 yr, M/F | Tehran | Cross sectional | PCR | Positive significant association between DD carriers and progression of albuminuria ($P < 0.01$) but not its development |
| Nikzamir et al., 2006 [105] | ACE/I/D | 85 T2DM/DN, 85 T2DM/non-DN, and 91 healthy, 37–67 yr, M/F | Tehran | Case control | PCR | Positive significant association between DD carriers and T2DM ($P = 0.006$) but not DN |
| Abbasi et al., 2013 [106] | GSTM1/null/positive | 80 DR and 80 healthy, 30–70 yr, M/F | Rasht | Case control | ARMS-PCR | Null genotype significant association, $P < 0.05$ |
| Dadbinpour et al., 2013 [107] | (i) GSTM1/null/positive (ii) GSTT1/null/positive | 57 DR and 58 non-DR, 35–65 yr, M/F | Yazd | Case control | Multiplex PCR | (i) Null genotype of GSTM1 or GSTT1 significant association ($P = 0.04$) (ii) Nonsignificant association of GSTT1 null carriers with DR |
| Feghhi et al., 2011 [108] | VEGF/+405G/C | 119 diabetics with PDR and 279 diabetics with NPDR, 47–66 yr, M/F | Ahvaz | Case control | PCR-RFLP | Positive significant association between GG carriers and diabetic retinopathy ($P = 0.005$) |
| Amoli et al., 2011 [109] | (i) VEGF/−7C/T (ii) VEGF/−2578C/A | 247 T2DM with DFU, 241 T2DM without DFU, and 98 healthy, 43–64 yr, M/F | Tehran | Case control | ARMS-PCR | (i) Nonsignificant association of −7C/T carriers with DFU (ii) Positive significant association between AA carriers and DFU ($P = 0.03$) |

SNP, single nucleotide polymorphism; T1DM, type 1 diabetes mellitus; CTLA-4, cytotoxic T lymphocyte associated antigen 4; T2DM, type 2 diabetes mellitus; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; IL, interleukin; SS-PCR, sequence specific PCR; VDR, vitamin D receptor; TAP2, transporter 2 ATP-binding cassette; ARMS-PCR, amplification refractory mutation system PCR; PCR-SSP, PCR single specific primer; TGFβ, transforming growth factor β; DM, diabetes mellitus; CTLA-4, cytotoxic T lymphocyte associated antigen 4; MODY, maturity onset diabetes of the young; HNF-1α, hepatocyte nuclear factor 1α; MVC, microvascular complications; TCF7L2, transcription factor 7-like 2; PCR-SSCA, PCR single strand conformation polymorphism analysis; ERα, estrogen receptor α; ND, nondiabetics; TC, total cholesterol; TG, triglycerides; PPAR-γ2, peroxisome proliferator-activates receptor γ; GLP-IR, glucagon-like peptide 1 receptor; APO, apolipoprotein; CXCL5, chemokine C-X-C motif ligand 5; SDF-1α, stromal derived factor-1α; IRS1 & 2, insulin receptor substrate 1 & 2; GST, glutathione-S-transferase; SLC30A8, soluble carrier 30A8; KCNJ, Potassium inwardly-rectifying channel; eNOS, endothelial nitric oxide synthase; VNTR, variable number of tandem repeats; ENPP1, ectoenzyme nucleotide pyrophosphatase phosphodiesterase 1; SUMO, small ubiquitin-like modifier 4; UCP2, uncoupling protein 2; MTHFR, methylenetetrahydrofolate reductase; IFNγ, interferon γ; CCR5, C-C chemokine receptor type 5; INS, insulin receptor; CSGE, conformation-sensitive gel electrophoresis; ACE, angiotensin I converting enzyme; HFE, hemochromatosis gene; PTPN11, protein tyrosin Phosphatase Hb; CAD, coronary artery disease; CETP, cholesteryl ester transfer protein; AT1R, angiotensin I receptor; MMP3, matrix metalloproteinase 3; CAS, coronary artery stenosis; BChE, Butyrylcholinesterase; K; DN, diabetic nephropathy; AT2R, angiotensin II receptor; VEGF, vascular epithelium growth factor; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; NPDR, non-PDR; DFU, diabetic foot ulcer.
3.2.1. T1DM Related Genes. All the studies in this subgroup including 12 studies [22–33] were in a case control study design using PCR (polymerase chain reaction) [33], PCR-RFLP (restriction fragment length polymorphism) [22, 23, 25, 26, 32], PCR-SSP (single specific primer) [24, 28–32], and ARMS-PCR (amplification refractory mutation system PCR) [27] method. In all studies both men and women were included and the overall 2519 subjects were under 40 years old.

Association of interleukins including IL-18 (interleukin) and IL-12 with T1DM revealed that the −137C/G polymorphism of IL-18 had significant association with T1DM (P = 0.037, P = 0.0001) while no significant relation was observed between −607A/C variant of this gene and T1DM [24, 28]. Investigating IL-12 also showed that there was a significant association between +1188A/C polymorphism of this gene and T1DM (P = 0.0035) [30].

In 2 studies the association of +49A/G variant of CTLA-4 (cytotoxic T lymphocyte associated antigen 4) was investigated and it was revealed that there was a positive significant association between AG genotype and T1DM (P = 0.01, P < 0.001) [22, 32]. One of these studies also revealed that there was a negative relation between AA genotype and T1DM [32].

Vitamin D receptor (VDR) was investigated in 2 studies [25, 26]. Both of them assessed the association of FokI, BsmI, Apal, and TaqI variants of VDR with T1DM. In one study which was performed on 114 subjects, Aa (P = 0.003), FF (P = 0.008) and Bb (P = 0.014) genotypes were shown to be positively associated with T1DM but no significant association was observed between TaqI polymorphism and T1DM [25]. Another study which was performed on 187 subjects showed no significant association between T1DM and FokI, BsmI, and Apal. However TT genotype was observed to be more frequent in controls (P = 0.007) and negatively associated with T1DM [26].

Different polymorphisms of TAP2 and their association with T1DM were investigated in 191 subjects. It was shown that Ile379Val and Stop687Gln had significant association with T1DM (P = 0.001 and P = 0.013, resp.). Other variants of TAP2 (transporter 2 ATP-binding cassette) including Ala565Thr, Arg651Cys, and Ala665Thr were not associated with T1DM significantly [27].

Association of alleles A2–A9 of CD4 with T1DM was assessed in 200 subjects. It was revealed that A3 allele had negative (P = 0.025) and A5 had positive (P = 0.001) significant association with T1DM [33].

Association of some other genes including osteopontin (rs1126772 polymorphism), integrin a4 (rs1449263 polymorphism), CD44 (rs8193 polymorphism), and TGFβ (transforming growth factor) (+915C/G polymorphism) was also investigated in 2 studies and no significant relation was observed between these variants and T1DM [23, 29].

3.2.2. MODY. In this category only one study was found [34] and the association of Val255Met polymorphism of HNF6 and diabetes was investigated in 101 subjects including MODY subjects, their relatives, and healthy controls [34]. The study was designed as a case control association study and PCR-RFLP and direct sequencing was used for genotyping of variants. Val255Met mutation in this investigation was observed in MODY subjects and their relatives but not in control group.

3.2.3. T2DM Related Genes. In this subgroup 42 studies were assessed and all of them were designed as case control association studies [22, 35–68, 70–75] except for one which was cross sectionally designed [69]. In 33 studies, PCR-RFLP was used for genotyping [22, 36–38, 40–54, 56, 58–61, 63–66, 69, 72–75]. In 5 of them PCR was used [35, 57, 62, 70, 71] and the remaining studies PCR-SCA [39], real-time PCR [55], ARMS-PCR [66], Gap PCR [67], and CSGE (conformation-sensitive gel electrophoresis) sequencing [68] as the genotyping method were applied.

Association between two polymorphisms of TCF7L2 including rs7903146 (C/T) and rs1225372 (G/T) was assessed in three studies [38, 48, 53]. In one study investigating rs7903146 (C/T) in 466 subjects, significant difference in the frequency of CC and CT genotypes was observed between T2DM and control group (P = 0.045) [38]. However in another study this polymorphism showed a positive significant association with TT genotype in T2DM (P = 0.008) [53].

Investigation of rs1225372 (G/T) polymorphism of TCF7L2 in another study showed that among 491 subjects there was a positive significant association between TT carriers and T2DM (P = 0.014) [48].

Investigating the association of calreticulin with T2DM in 650 subjects showed two mutations, only in case group, 9 bp deletion of 397–399 codons and G>T mutation at IVSII-142 [39].

Association of estrogen receptor α and its PvuII (PP, Pp, pp) and Xbal(XX,Xx,xx) polymorphism with T2DM in two studies was assessed [40, 49]. In one study, the significant association of PvuII and Xbal polymorphisms with T2DM was observed (P = 0.014 and P = 0.002, resp.) [40]. In another study it was revealed that pooled Pp+pp and XX+xx male carriers have positive significant association with T2DM (P = 0.001 and P = 0.026, resp.) [49].

Association of Pro12Ala polymorphism of PPARγ with T2DM was investigated in three studies [41, 69, 75]. Negative significant association of Ala/Ala genotype with T2DM was observed in two studies (P = 0.003) [41, 75]. Ala/Pro carriers were shown to be positively associated in one study [41] and negatively associated in another study [75] with T2DM (P < 0.001 and P = 0.003, resp.). However in the third study no significant association was observed between Pro12Ala polymorphism of PPARγ and T2DM [69].

Association of different polymorphisms of ApoAI with T2DM was investigated in two studies [43, 72]. In one study investigation of MSPI polymorphism showed no significant association with T2DM [43]. In another study it was shown that G-75A polymorphism of ApoAI was not associated with T2DM while a significant association was found between C+83T polymorphism and T2DM (P = 0.028) [72].

Two studies assessed the association of −156G>C polymorphism of CXCL5 with T2DM [44, 65]. In one study positive significant association of GC carriers (P = 0.006) and negative association of GG carriers (P = 0.01) was found between diabetic patients and healthy controls [44] and
in another study positive significant association was found between GC or CC carriers and T2DM \( (P = 0.009) \) [64].

Adiponectin and its association with T2DM were investigated in two studies [56, 73]. In one study, two variants including +45T/G and −1139G/A were investigated but no significant relation was found between these two polymorphisms and T2DM [56]. However in another study investigating +45T/G polymorphism of adiponectin, it was revealed that nonobese T2DM subjects had significantly higher TT genotype \( (P = 0.04) \) [73].

In one study that investigated insulin receptor gene, the following mutations were found only in T2DM: 51IC>A, 514T>G, 586, and 628T>A on exon 2, 694G>C, 680G>A on exon 3, 1627A>T on exon 8, A1>TG on intron 9, 2007C>C/T on exon 9, 2595C>C/T and 2669G>C/G on exon 13, 2706 and 2717C>G, 2752C>G, and 2753C>G on exon 14, and 3471T>A and 3516T>G on exon 19. These mutations were not seen in control subjects [68].

Other variants which had significant association with T2DM included haptoglobin (allele 2-2), leptin (G-2548A polymorphism), paraoxonase 2 (Ser314Cys polymorphism), GST (glutathione-S-transferase) M1 and GSTM1/GSTT1 interaction, calpain-10, RAS (single nucleotide polymorphism) 43, IRS-1 (G972R polymorphism) and IRS-2 (G1057D polymorphism), VDR (vitamin D receptor) (Taql polymorphism), KCNJ11 (E23K polymorphism), and eNOS (endothelial nitric oxide synthase) VNTR (intron 4 a/b polymorphism), resistin (−420C/G polymorphism), and ACE (Insertion/Deletion) [35–37, 45, 47, 50, 55, 57, 58, 64, 60, 70].

In contrast to above variants, CTLA4 (+49A/G polymorphism), HNF-1 (γ factor) (+874T/A polymorphism), CCR5 (C-C chemokine receptor type 5) (+49A/G polymorphism), CTLA4 (+49A/G polymorphism of butyrylcholinesterase (BChE) K) and apolipoprotein E (ApoE) was associated significantly with CAD and diabetes. ApoE4/BChE K had significant association with lipid profiles as well \( (P < 0.05) \) [87].

3.2.5. Genes Related to Cardiovascular Disease in Diabetes.

Investigating B1 and B2 alleles of CETP TaqI B allele in 400 subjects showed that pooling of B1B1+B1B2 and B1B1 genotypes had significant association with T2DM and CAD \( (P < 0.01) \). On the other hand assessing the G894T polymorphism of eNOS showed positive significant association between TG and TT carriers and CAD \( (P < 0.05) \). It was also shown that concomitant presence of NOS3 T allele and CEPT B1 allele was significantly associated with T2DM \( (P = 0.004) \) and CAD \( (P = 0.002) \) [83].

Investigation of apolipoprotein E (E2, E3, and E4) alleles showed the association of E2 and E4 alleles with CAD \( (P < 0.001) \) [84, 87]. Also it was shown that interaction of butyrylcholinesterase (BChE) K and apolipoprotein E (ApoE) was associated significantly with CAD and diabetes. ApoE4/BChE K had significant association with lipid profiles as well \( (P < 0.05) \) [87].

Adiponectin +276G/T and +45T/G were significantly associated with CAD \( (P = 0.023 \) and 0.033, resp.) [82] while investigating −1612 5A/6A polymorphism of MMP-3 (matrix metalloproteinase 3) showed a significant association with CAS (coronary artery stenosis) \( (P = 0.008) \) [86].

In addition A1666C polymorphism of AT1R (angiotensin I receptor) and −420C/G polymorphism of resistin in diabetic patients with CAD revealed significant association with diabetes, \( P = 0.01 \) and \( P = 0.009 \), respectively [84, 85].

Another study showed insertion/(I)/deletion(D) polymorphism of angiotensin converting enzyme (ACE) DD genotype was significantly associated with higher blood pressure \( (P = 0.026) \) [89].

Factor V Leiden (G1691A polymorphism), prothrombin (G20210A polymorphism), and MTHFR (methylene tetrahydrofolate reductase) (C677T polymorphism) were the variants which were not significantly associated with CAD and T2DM in this subgroup [88].

3.2.6. Genes Related to Diabetic Nephropathy.

All of 15 studies in this subgroup were designed as case-control association studies [91–106]. In 7 studies, PCR-RFLP was used for genotyping [92–95, 99, 102, 103]; in four studies PCR was used [98, 101, 104, 105] and in 4 of them both PCR and PCR-RFLP were used [91, 96, 97, 100].
Studying the association of 163A/G polymorphism of SUMO4 showed a positive significant association between AA carriers and diabetic nephropathy \( (P < 0.05) \) [93].

Studying the interaction of eNOS/4a/b and G894T revealed positive significant association between 4a or 894T allele carriers and macro- and microalbuminuria \( (P = 0.01, P = 0.02, \text{resp.}) \) [91]. It was observed that the interaction of eNOS (G894T polymorphism) and ACE (I/D alleles) was significantly associated with more frequent macroalbuminuria \( (P = 0.035) \) [97].

It has also been shown that interaction of eNOS (G894T polymorphisms) and MTHFR (C677T and A1298C polymorphisms), eNOS T1298 C, and eNOS T677 T carriers had positive significant association with macroalbuminuria. In addition significant association of eNOS GT+TT carriers with lipid profile \( (P < 0.05) \) was shown in this study [99].

C677T and A1298C polymorphisms of MTHFR were also investigated in another study revealing that 677T, 1298C, and 677T/1298C carriers were significantly associated with macroalbuminuria \( (P < 0.001) \). Positive significant association when pooling CT+TT genotypes and 677T/1298C was also found with microalbuminuria \( (P < 0.001) \) [103]. Investigating the interaction of MTHFR (A1298C, C677T polymorphisms) and ACE (I/D alleles) showed a positive significant association of ACE D/677T \( (P = 0.035) \) and ACE D/1298C \( (P = 0.012) \) genotypes with macroalbuminuria [96].

ACE (I/D alleles) polymorphisms were investigated in three studies. In one study positive significant association \( (P < 0.01) \) between DD carriers and progression but not development of albuminuria was observed [104]. In another study in nephropathic subjects, association of DD carriers and T2DM \( (P = 0.006) \) but not nephropathy was revealed [105]. However another study did not show significant association of ACE with macroalbuminuria [98]. Interaction of ACE (I/D alleles) with Factor V Leiden (G1691A polymorphism) was not significant [100].

Apsociation of interleukins including IL-4 and IL-10 with diabetic nephropathy was also investigated in two studies. Study of −592C/A polymorphism of IL-10 revealed positive significant association between CC carriers and nephropathy \( (P = 0.001) \) [94] and study of −590C/T polymorphism of IL-4 revealed positive significant association between CT carriers and nephropathy \( (P < 0.001) \) [101].

Other significant associations between variants and diabetic nephropathy included AT2R (angiotensin II receptor) (−1332G/A polymorphism), VEGF (vascular epithelium growth factor) (+405G/C polymorphism), and VDR (TaqI polymorphism) [92, 95, 102]. Apal polymorphism of VDR was not significantly associated with diabetic nephropathy [102].

3.2.7. Genes Related to Diabetic Retinopathy. All of the 3 studies in this subgroup were conducted as case-control association studies [106–108].

Investigating null/positive genotype of GSTM1 in a study, which used ARMS-PCR for genotyping, revealed that null genotype is significantly associated with diabetic retinopathy \( (P < 0.05) \) [106]. This result was confirmed in another study by using multiplex PCR as genotyping [107], although no significant association between GSTT1 and retinopathy was found in this study [107].

Investigating +405G/C polymorphism of VEGF also revealed positive significant association between GG carriers and diabetic retinopathy \( (P = 0.005) \) [108].

3.2.8. Genes Related to Diabetic Foot Ulcer. In this subgroup only one study was found [109] which was case-control designed and used ARMS-PCR for genotyping. In this study association of −7C/T and −2578C/A polymorphisms of VEGF with diabetic foot ulcer (DFU) was investigated, and a positive significant association between AA carriers and DFU \( (P = 0.03) \) was observed. But no significant association was found between −7C/T of VEGF and DFU [109].

4. Discussion

Diabetes mellitus is the eighth most frequent disease leading cause of death throughout the world and now ranks the fifth, following communicable diseases, cardiovascular disease, cancer, and injuries [110]. Prevalence of diabetes mellitus is increasing worldwide [6].

Type 2 diabetes is the most frequent type of diabetes mellitus [110, 111]. Multiple genes and environmental factors affect the prevalence of T2DM. Systematic review and meta-analysis studies have assessed the association between different genes and T2DM. Glutathione-S-transferase including GSTM1, GSTM1, and GSTP1 are important genes and their association with diabetes has been investigated in two meta-analysis studies [112, 113]. It was revealed that null genotype of both GSTM1 and GSTT1 could be as a risk factor for diabetes while no significant association was found between GSTP1 and diabetes [112, 113]. These results are in line with our finding and confirming the association of the null genotype of GSTT1 and GSTM1 with T2DM in Iranian population [50]. The relation between GSTT1 and GSTM1 and diabetic retinopathy has also been shown in Iranian population [106, 107].

MTHFR is another important gene in association with T2DM and other related complications. No association of C677T polymorphism of MTHFR gene was found in Africans, Asians, and Caucasians [114]. MTHFR is a gene which is involved in DNA methylation and synthesis and regulated folate activity. It has been reported that mutant homozygote and heterozygote of C677T polymorphism of MTHFR increase plasma homocysteine which is an important factor leading to diabetic nephropathy (DN) and, as a result, C677T polymorphism of MTHFR can be associated with the development of DN. In Caucasians this association has also been observed [115]. In Iranian population, in line with other populations, no significant association was found between MTHFR polymorphisms and T2DM [63] although significant association of 677T and 1298C alleles with diabetic nephropathy was observed [87]. Interaction of two polymorphisms and also interaction of MTHFR polymorphisms with other genes such as ACE and eNOS showed an association with development of DN [96, 99].
Interleukins especially IL-10 are shown to have significant association with T2DM in different ethnic groups. Significant association between −592C/A and −819C/T polymorphisms of IL-10 and T2DM risk in Africans was shown [116]. Also −1082A/G polymorphism of IL-10 seems to be a risk factor for T2DM in Asians but not in Europeans and Africans [116]. In another study it was reported that −1082GG genotype of IL-10 and −174CC genotype of IL-6 are as risk factors for T2DM in Egyptians [117]. In our study IL-4 has been studied but no significant association with T2DM was seen [66].

Investigation of different polymorphisms of adiponectin and their association with T2DM in a meta-analysis study revealed −1139G>A and −11426A>G polymorphisms of adiponectin as risk factor for T2DM in Europeans and −1377C>G variant of adiponectin as risk factor of T2DM in Europeans and Asians [110]. It was also shown that +45T>G and +276G>T variants are not associated with T2DM in Europeans, Africans, and Asians [110]. In contrast to previous studies, +45T>G and −1139G>A polymorphisms were not associated with T2DM in this study due to difference in genetic background [56].

Among candidate genes in association with T2DM, TCF7L2 is one of the strongest genes related to diabetes. In a meta-analysis study after pooling all data of European, African, and Asian populations, it has been revealed that rs12255372 polymorphism of TCF7L2 significantly increases the risk of T2DM. However no data from Iranian population as a type of Asian population was included in this meta-analysis [111]. In line with these data, in our study, we found a positive association between rs12255372 and rs7903146 variants of TCF7L2 and T2DM [38, 48, 53].

Pro12Ala polymorphism of PPARγ is found to be as a protective variant especially in Asian population although the results were highly heterogeneous [118]. In our study the results were controversial. In one study no association was found between this polymorphism and T2DM in contrast with previous studies [69] while in other studies protective effect of this polymorphism with T2DM was confirmed in line with previous studies [41, 75]. These controversial data may be due to different ethnicity in different populations being studied in Iran. Small sample size could be another reason for the controversial results.

Type 1 diabetes mellitus is another type of diabetes in which HLA (human lymphocyte antigen), IRIRI (interleukin-1 receptor type 1), CTLA-4, and VDR are some important genes studied in association with T1DM [119]. VDR is one of the most studied genes in relation to T1DM due to its role in T-cell mediated autoimmune diseases [119, 120]. Meta-analysis studies showed that BsmI and FokI polymorphisms of VDR increased the risk of T1DM in East and West Asians, respectively [119]. In our study, controversial results were found. In one study BsmI was shown to be associated with T1DM [25] while in another study no association was found [26]. FokI was not associated with T1DM in our study in contrast to previous studies which might be due to difference in ethnicity and genetic background or insufficient clinical data [25, 26].

Among diabetic complications, CAD and DN are the most studied complications. Meta-analysis studies showed that rs2010963 and rs3025039 polymorphisms of VEGF, 4b/a, T-786C, and G894T polymorphisms of eNOS and ACE are associated with DN [121–123]. In our study, 4a/b and G894T polymorphisms of eNOS and ACE were shown to be associated with DN in line with previous studies [91, 104, 105]. In our study rs2010963 polymorphism of VEGF was also found to be associated with diabetic nephropathy which was in line with previous studies [95].

The most investigated genes in association with CAD include PPARγ, TCF7L2, ACE, TNF-α, adiponectin, and IRS1 [118]. In our study, +45T>G and +276G>T polymorphisms of adiponectin were investigated and the significant association of these variants with CAD was confirmed [82].

Overall it seems that more studies are needed to identify diabetes susceptibility genes in Iranian population. Investigation of candidate genes is one way to understand these genes, but the method with the least expenses and error is GWAS which scans a set of loci in association with a disease in many people. GWAS in different populations such as Americans, Caucasians, Australians, West Africans, and Europeans revealed multiple loci in association with T2DM [124–128]. In Asians especially in Middle Eastern countries GWAS is critically needed. In our investigations, we reviewed five studies which investigated the association between eNOS, ACE, MTHFR, and factor V Leiden and the interaction between them and diabetic nephropathy and reach a coherent result [91, 97, 99, 100, 104] while GWAS could be helpful and reduce time and other expenses [126].

However, there are some strength and some limitations in our study. Firstly, this systematic review, for the first time, assessed the association between genetic variants and diabetes in Iranian population. Moreover, the studies included in this systematic review were assessed for quality and selected as high quality (scored ≥3). For limitations it should be considered that all included studies were observational, which does not allow reliable inferences about causality. Moreover due to methodological heterogeneity, we were not able to pool the data and perform the meta-analysis.

5. Conclusion

Our study showed significant association between CTLA-4, IL-18, VDR, TAP2, IL-12, and CD4 genes and T1DM. HNF4x gene had significant association with MODY. The following genes showed significant association with T2DM: haptoglobin, paraoxonase, leptin, TCF7L2, calreticulin, ERα, PPAR-γ2, CXCL5, calpain-10, IRS-1 and 2, GSTM1, KCNJ11, eNOS, VDR, resistin, INSR, ACE, ApoA-I, adiponectin, and PTPN1. In assessment of association between CAD and diabetes in Iranian population the following genes showed significant association: paraoxonase 1, adiponectin, eNOS, CETP, ATIR, resistin, MMP-3, BChE K, Apo E, ACE. The following genes had significant association with diabetic nephropathy: eNOS, AT2R, SUMO4, IL-10, VEGF, MTHFR, ACE, and VDR. The following genes had significant association with diabetic retinopathy: GSTM1 and VEGF and also VEGF had significant association with diabetic foot ulcer.

Insufficient data might cause the conflicting results; therefore GWAS on defined population with large sample size
is suggested as a more comprehensive approach answering many more questions.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**References**

[1] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” *Diabetes Care*, vol. 27, Supplement 1, pp. S5–S10, 2004.

[2] World Health Organization (WHO), *Diabetes Mellitus, Report of a WHO Expert Committee*, WHO Technical Report Series no. 310, World Health Organization, Geneva, Switzerland, 1965.

[3] World Health Organization (WHO), “WHO expert committee on diabetes mellitus,” *WHO Technical Report Series No. 646*, World Health Organization (WHO), Geneva, Switzerland, 1980.

[4] International Diabetes Federation, *IDF Diabetes Atlas*, International Diabetes Federation, 6th edition, 2013, http://www.idf.org/diabetesatlas.

[5] F. Najafipoor, F. Azizi, and M. Zareizadeh, “Epidemiologic investigation of familial type 2 diabetes in Tehran,” *Iranian Journal of Diabetes and Lipid Disorders*, vol. 4, no. 1, pp. 35–42, 2004.

[6] IDF Diabetes Atlas, *New Estimates for 2012 of Diabetes Prevalence, Mortality, and Healthcare Expenditures*, 5th edition, 2012, http://www.idf.org/.

[7] A. A. Haghdoost, M. Rezaizadeh-Kermani, B. Sadghirad, and H. R. Baradaran, “Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis,” *Eastern Mediterranean Health Journal*, vol. 15, no. 3, pp. 591–599, 2009.

[8] S. M. Akrami, “Genetic counseling in diabetes,” *Iranian Journal of Diabetes and Lipid Disorders*, vol. 6, no. 3, pp. 205–213, 2007.

[9] National Diabetes Data Group, “Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance,” *Diabetes*, vol. 28, no. 12, pp. 1039–1057, 1979.

[10] K. Xiang, Y. Wang, T. Zheng et al., “Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese,” *Diabetes*, vol. 59, pp. 228–234, 2004.

[11] T. H. Luo, Y. Zhao, G. Li et al., “A genome-wide search for type II diabetes susceptibility genes in Chinese Hans,” *Diabetologia*, vol. 44, no. 4, pp. 501–506, 2001.

[12] O. Ali, “Genetics of type 2 diabetes,” *World Journal of Diabetes*, vol. 4, no. 4, pp. 114–123, 2013.

[13] I. Prokopenko, M. I. McCarthy, and C. M. Lindgren, “Type 2 diabetes: new genes, new understanding,” *Trends in Genetics*, vol. 24, no. 12, pp. 613–621, 2008.

[14] S. Abbas, S. T. Raza, F. Ahmed, A. Ahmad, S. Rizvi, and F. Mahdi, “Association of genetic polymorphism of PPARG-2, ACE, MTHFR, FABP-2 and FTO genes in risk prediction of type 2 diabetes mellitus,” *Journal of Biomedical Science*, vol. 20, no. 1, pp. 80–88, 2013.

[15] Q.-Y. Huang, M.-R. Cheng, and S.-L. Ji, “Linkage and association studies of the susceptibility genes for type 2 diabetes,” *Acta Genetica Sinica*, vol. 33, no. 7, pp. 573–589, 2006.

[16] S. Li, H. J. Shin, E. L. Ding, and R. M. van Dam, “Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis,” *The Journal of the American Medical Association*, vol. 302, no. 2, pp. 179–188, 2009.

[17] S. Bakhtiari, A. Babakhani, M. H. Maleki et al., “Investigation of the association between rs2970847 polymorphism of PGC-1α gene and type 2 diabetes mellitus, a systematic review and meta analysis,” *Journal of Research of Medical School of Shahid Beheshti University*, vol. 36, pp. 104–110, 2012.

[18] H. Ounissi-Benkalha et al., “The molecular genetics of type 1 diabetes: new genes and emerging mechanisms,” *Trends in Molecular Medicine*, vol. 14, no. 6, pp. 268–275, 2008.

[19] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” *British Medical Journal*, vol. 339, Article ID b2535, 2009.

[20] World Health Organization (WHO), “Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia,” Report of a WHO/IDF Consultation, 2006.

[21] J. P. Vandenbroucke, E. von Elm, D. G. Altman et al., “Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration,” *PLoS Medicine*, vol. 4, no. 10, article e297, 2007.

[22] S. Ahmad, J. Rostamzadeh, D. Khosravi, P. Shariat, and N. Shakiba, “Association of CTLA-4 gene 49A/G polymorphism with the incidence of type 1 diabetes mellitus in the Iranian Kurdish population,” *Pakistan Journal of Biological Sciences*, vol. 16, no. 24, pp. 1929–1935, 2013.

[23] Z. Karamizadeh et al., “Investigation of osteopontin levels and genomic variation of osteopontin and its receptors in type 1 diabetes mellitus,” *Journal of Endocrinological Investigation*, vol. 36, no. 11, pp. 1090–1093, 2013.

[24] M. Rahbani-Nabar, A. Rezaie, S. Bazzaz, and N. A. Zadeh, “Association of 137 polymorphism in the interleukin-18 gene promoter with diabetes mellitus type I in East Azerbaijan population,” *Medical Journal of Tabriz University of Medical Sciences and Health Services*, vol. 35, no. 2, pp. 38–43, 2013.

[25] S. Bonakdaran, M. R. Abbaszadegan, E. Dadihkhah, and M. Khajee-Dalouie, “Vitamin D receptor gene polymorphisms in type 1 diabetes mellitus: a new pattern from Khorasan province, Islamic Republic of Iran,” *Eastern Mediterranean Health Journal*, vol. 18, no. 6, pp. 614–619, 2012.

[26] Z. Mohammadnejad, M. Ghanhari, R. Ganjali et al., “Association between vitamin D receptor gene polymorphisms and type 1 diabetes mellitus in Iranian population,” *Molecular Biology Reports*, vol. 39, no. 2, pp. 831–837, 2012.

[27] J. T. Afshari, S. M. Taghavi, S. S. Fatemi, H. Rafatpanah, F. Ghaybi, and N. Nezamdoost, “TAP2 polymorphisms in Iranian patients with type I diabetes mellitus,” *International Journal of Genetics and Molecular Biology*, vol. 3, no. 8, pp. 115–119, 2011.

[28] A. Massoud, N. Sheikh Bahai, M. Massoud et al., “IL18 gene polymorphism in type I diabetic patients: a case-control study,” *Tehran University Medical Journal*, vol. 67, no. 1, pp. 20–24, 2009.

[29] M. Massoud, I. Salehi, N. Sheykhabahaiy, M. Voigani, A. A. Rajab, and A. Massoud, “Investigation of codon 25 polymorphism of TGFβ gene in type 1 diabetes mellitus patients,” *Journal of Medical Faculty Guilan University of Medical Sciences*, vol. 16, no. 62, pp. 1–6, 2007.

[30] A. H. Masoud, A. Keihani, N. Sheykhabahaiy et al., “Investigation of polymorphism of IL-12 in type I diabetes mellitus patients,” *Medical Journal of Mashhad University of Medical Sciences*, vol. 50, no. 97, pp. 283–286, 2007.
[57] M. Mehrab-Mohseni, O. Tabatabaei-Malazy, S. Hasani-Ranjbar et al., "Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications," Diabetes Research and Clinical Practice, vol. 91, no. 3, pp. 348–352, 2011.

[58] R. Nosratabadi, M. K. Arababadi, and V. A. Salehabad, "Vitamin D receptor polymorphisms in type 2 diabetes in southeastern Iranian patients," Laboratory Medicine, vol. 42, no. 1, pp. 32–34, 2011.

[59] H. Saberi, N. Mohammadtaghvaei, S. Gulkho et al., "The ENPP1 K121Q polymorphism is not associated with type 2 diabetes and related metabolic traits in an Iranian population," Molecular and Cellular Biochemistry, vol. 350, no. 1-2, pp. 113–118, 2011.

[60] S. Fallah, M. Jafarzadeh, and M. Hedayati, "No association of SUMO4 polymorphism M55V variant in type 2 diabetes in Iranian subjects," Diabetes Research and Clinical Practice, vol. 90, no. 2, pp. 191–195, 2010.

[61] J. Heidari, S. M. Akrami, R. Heshmat, P. Amiri, H. Fakhrzadeh, and M. Pajouhi, "Association study of the –866G/A UCP2 promoter polymorphism with type 2 diabetes and obesity in a tehran population: a case control study," Archives of Iranian Medicine, vol. 13, no. 5, pp. 384–390, 2010.

[62] H. Nazem, M. A. Takshid, S. M. B. Tabei, F. Sholevar, M. Entezam, and J. Manoochehri, "Investigation of association between serotonin transporter gene and type 2 diabetes mellitus," Iranian Journal of Diabetes and Lipid Disorders, vol. 10, no. 1, pp. 84–89, 2010.

[63] J. T. Bazzaz, M. Shojapoor, H. Nazem et al., "Methylenetetrahydrofolate reductase gene polymorphism in diabetes and obesity," Molecular Biology Reports, vol. 37, no. 1, pp. 105–109, 2010.

[64] S. Emamgholipour, A. Hasani-Ranjbar, P. Amiri, M. Namakchian et al., "Investigation of association between CXCL5 gene polymorphism and diabetes and related metabolic traits in an Iranian population," Molecular Biology Reports, vol. 37, no. 1, pp. 105–109, 2010.

[65] S. Hasani-Ranjbar, A. Monfaredan, K. Bargahi, H. Mirzaei et al., "Investigation of association between apoAI gene polymorphism with insulin resistance in diabetic patients," European Journal of Experimental Biology, vol. 3, no. 5, pp. 453–458, 2009.

[66] H. Mirzaei, S. M. Akrami, T. Golmohammedi et al., "Polymorphism of Pro12Ala in the peroxisome proliferator-activated receptor 2 gene in Iranian diabetic and obese subjects," Metabolic Syndrome and Related Disorders, vol. 7, no. 5, pp. 453–458, 2009.

[67] A. Nikzamir, M. Nakhjavani, T. Golmohammedi, L. Dibai, and R. Saffary, "Polymorphism in the angiotensin-converting enzyme (ACE) gene and ACE activity in type 2 diabetic patients," Acta Medica Iranica, vol. 46, no. 4, pp. 277–282, 2008.

[68] F. Sharifi, A. Esmaeilzadeh, and M. Zali, "Hemochromatosis gene (HFE) mutations in patients with type 2 diabetes and their control group in an Iranian population," Saudi Medical Journal, vol. 29, no. 6, pp. 808–812, 2008.

[69] A. Besharati, S. M. Akrami, R. Heshmat, P. Yaghmaee, and R. Alikazemi, "Investigation of association between apoAI gene polymorphisms and lipid profiles and type 2 diabetes mellitus in Iranian population," Journal of Islamic Republic of Iran Medical Council, vol. 25, no. 2, pp. 132–141, 2007.

[70] S. Hasani-Ranjbar, J. Tavakkoly Bazzaz, P. Amiri, M. M. Amoli, and B. Larijani, "Investigation of the frequency of +45T/G polymorphism of adiponectin gene in type 2 diabetic patients in a Tehranian population," Iranian Journal of Diabetes and Lipid Disorders, vol. 6, no. 3, pp. 215–218, 2007.

[71] R. Meshkani, M. Taghikhani, H. Al-Kateb et al., "Polymorphisms within the protein tyrosine phosphatase IB (PTPNI) gene promoter: functional characterization and association with type 2 diabetes and related metabolic traits," Clinical Chemistry, vol. 53, no. 9, pp. 1585–1592, 2007.

[72] R. Meshkani, M. Taghikhani, B. Larijani et al., "Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ (PPARγ-2) gene is associated with greater insulin sensitivity and decreased risk of type 2 diabetes in an Iranian population," Clinical Chemistry and Laboratory Medicine, vol. 45, no. 4, pp. 477–482, 2007.

[73] F. Namvaran, M.-P. Rahimi, N. Azarpira, and M. H. Dabbaghmanesh, "Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus," Molecular Biology Reports, vol. 39, no. 5, pp. 5511–5518, 2012.

[74] F. Namvaran, N. Azarpira, P. Rahimi-Moghadam, and M. H. Dabbaghmanesh, "Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes," European Journal of Pharmacology, vol. 671, no. 1–3, pp. 1–6, 2011.

[75] A. Hossein-nezhad, K. Mirzaei, P. Shabani et al., "Association of VDR gene polymorphism with insulin resistance in diabetic patient's running title: VDR and insulin resistance," Iranian Journal of Diabetes and Lipid Disorders, vol. 8, no. 1, pp. 143–149, 2009.

[76] A. Moosapoor, M. Taghikhani, R. Meshkani, S. Khatami, S. Bakhhtiari, and K. Haghani, "Association of 3′ UTR (1484insG) polymorphism of PTP1B gene with Type 2 diabetes, insulin resistance and obesity in a Tehranian population," Journal of School of Public Health and Institute of Public Health Research, vol. 5, no. 3, pp. 1–13, 2007.

[77] R. Bayatmakoo, H. Mobaiyen, A. Monfaredan, K. B. Sofiani, and R. Benissy, "The study of effects common paraoxonase polymorphism (L55M) on atherosclerosis risk in diabetic patients by PCR-RFLP," European Journal of Experimental Biology, vol. 3, no. 3, pp. 512–516, 2013.

[78] R. Bayatmakoo, A. Monfaredan, N. Bargahi, H. Mobaiyen, and N. Aslanabadi, "Paraoxonase gene polymorphism and atherosclerosis risk in diabetic patients," Journal of Azad University of Medical Sciences, vol. 22, no. 3, pp. 191–197, 2012.

[79] A. Esteghamati, N. Mansournia, M. Nakhjavani, M. A. Mansournia, A. Nikzamir, and M. Abbasi, "Association of +45T/G and +276(G/T) polymorphisms in the adiponectin gene with coronary artery disease in a population of Iranian patients with type 2 diabetes," Molecular Biology Reports, vol. 39, no. 4, pp. 3791–3797, 2012.
A. Vaisi-Raygani, R. Nourozi-Rad, and A. Parsian, “Strong interaction between T allele of endothelial nitric oxide synthase with B1 allele of cholesterol ester transfer protein TaqIB highly elevates the risk of coronary artery disease and type 2 diabetes mellitus,” Human Genomics, vol. 6, article 20, 2012.

A. Assali, M. Ghayour-Mobarhan, A. Sahebkar et al., “Association of angiotensin II type 1 receptor gene A1166C polymorphism with the presence of diabetes mellitus and metabolic syndrome in patients with documented coronary artery disease,” European Journal of Internal Medicine, vol. 22, no. 3, pp. 254–261, 2011.

S. Emamgholipour, A. Hossein-nezhad, S. A. Mohajerani, M. Shirzad, and B. Larijani, “Association between promoter resistin gene polymorphism and coronary artery disease in diabetic and non diabetic patients,” Iranian Journal of Diabetes and Lipid Disorders, vol. 10, no. 2, pp. 221–228, 2009.

S. Fallah, M. Seifi, and A. Samadikuchaksarai, “Risk of coronary artery stenosis in Iranian type 2 diabetics: is there a role for matrix metalloproteinase-3 gene (−1612 5A/6A) polymorphism?” Journal of Physiology and Biochemistry, vol. 66, no. 4, pp. 359–364, 2010.

A. Vaisi-Raygani, Z. Rahimi, H. Tavilani, and T. Pourmotabbed, “Butyrylcholinesterase K variant and the APOE-epsilon4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients,” Molecular Biology Reports, vol. 37, no. 4, pp. 2083–2091, 2010.

Z. Rahimi, H. Nomi, H. Mozafari et al., “Factor v G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran,” Blood Coagulation & Fibrinolysis, vol. 20, no. 4, pp. 252–256, 2009.

M. Nakhjavani, F. Esfahanian, A. Jahanshahi et al., “The relationship between the insertion/deletion polymorphism of the ACE gene and hypertension in patients with type 2 diabetes,” Nephrology Dialysis Transplantation, vol. 22, no. 9, pp. 2549–2553, 2007.

A. Vaisi-Raygani, Z. Rahimi, H. Nomi, H. Tavilani, and T. Pourmotabbed, “The presence of apolipoprotein $\varepsilon 4$ and $\varepsilon 2$ alleles augments the risk of coronary artery disease in type 2 diabetic patients,” Clinical Biochemistry, vol. 40, no. 15, pp. 1150–1156, 2007.

Z. Rahimi, F. Shahvaisi-Zadeh, S. Sadeghei, M. Vessential, and N. Yavari, “eNOS 4a/b polymorphism and its interaction with eNOS G894T variants in type 2 diabetes mellitus: modifying the risk of diabetic nephropathy,” Disease Markers, vol. 34, no. 6, pp. 437–443, 2013.

Z. Rahimi, O. Mansouri Zaveleh, Z. Rahimi, and A. Abbasi, “AT2R -1332 G:A polymorphism and diabetic nephropathy in type 2 diabetes mellitus patients,” Journal of Renal Injury Prevention, vol. 2, no. 3, pp. 97–101, 2013.

E. Shahsavaran, A. Kheirollaah, M. Jafarzadeh, and M. Hedayati, “SUMO4 M55 Polymorphism is associated with diabetic nephropathy in Iranian type 2 diabetes patients,” Life Science Journal, vol. 10, no. 5, pp. 485–487, 2013.

M. K. Arababadi, M. R. Mirzaei, S. M. A. Sajadi et al., “Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the Southeast Region of Iran,” Inflammation, vol. 35, no. 3, pp. 797–802, 2012.

A. Nikzamir, A. Esteghamati, A. A. Hammadian, and T. Mahmoudi, “The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus,” Molecular Biology Reports, vol. 39, no. 2, pp. 881–886, 2012.

Z. Rahimi, A. Hasanvand, and V. Felehgari, “Interaction of MTHFR 1298C with ACE D allele augments the risk of diabetic nephropathy in Western Iran,” DNA and Cell Biology, vol. 31, no. 4, pp. 553–559, 2012.

Z. Rahimi, A. Vaisi-Raygani, and A. Parsian, “Concomitant presence of endothelial nitric oxide 894T and angiotensin II-converting enzyme D alleles are associated with diabetic nephropathy in a Kurdish population from Western Iran,” Nephrology (Carlton, Vic), vol. 17, no. 2, pp. 175–181, 2012.

V. Felehgari, Z. Rahimi, H. Mozafari, and A. Vaisi-Raygani, “ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria,” Molecular and Cellular Biochemistry, vol. 346, no. 1-2, pp. 23–30, 2011.

Y. Jafari, Z. Rahimi, V. Felehgari, and M. Rezaei, “Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients,” Molecular and Cellular Biochemistry, vol. 353, no. 1-2, pp. 23–34, 2011.

M. K. Arababadi, “Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy,” Iranian Journal of Kidney Diseases, vol. 4, no. 4, pp. 302–306, 2010.

R. Nosratabadi, M. K. Arababadi, V. A. Salehabad et al., “Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes,” International Journal of Immunogenetics, vol. 37, no. 6, pp. 493–497, 2010.

M. Rahimi, A. Hasanvand, Z. Rahimi et al., “Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus,” Clinical Biochemistry, vol. 43, no. 16-17, pp. 1333–1339, 2010.

A. Nikzamir, A. Esteghamati, M. Feghhi, M. Nakhjavani, A. Rashidi, and J. Z. Reza, “The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 10, no. 2, pp. 109–114, 2009.

A. R. Nikzamir, T. Golmohammadi, M. Nakhjavani, M. Zahrara, and A. A. Amirzargar, “Angiotensin converting enzyme gene polymorphism in Iranian patients with type 2 diabetes,” Iranian Journal of Immunology, vol. 3, no. 1, pp. 23–29, 2006.

N. Abbasi, Z. Salehi, and Y. Alizadeh, “Analysis of glutathione S-transferase M1 (GSTM1) deletion in diabetic retinopathy,” Journal of Guilan University of Medical Sciences, vol. 88, pp. 34–40, 2013.

A. Dadinpour, M. Sheikhha, M. Darbouy, and M. Afkhami-Ardekan, “Investigating GSTT1 and GSTM1 null genotype as the risk factor of diabetes type 2 retinopathy,” Journal of Diabetes & Metabolic Disorders, vol. 12, no. 1, pp. 48–53, 2013.
[108] M. Feghhi, A. Nikzamir, A. Esteghamati, T. Mahmoudi, and M. S. Yekaninejad, "Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes," Translational Research, vol. 158, no. 2, pp. 85–91, 2011.

[109] M. M. Amoli, S. Hasani-Ranjbar, N. Roohipour et al., "VEGF gene polymorphism association with diabetic foot ulcer," Diabetes Research and Clinical Practice, vol. 93, no. 2, pp. 215–219, 2011.

[110] H. Chu, M. Wang, D. Zhong et al., "AdipoQ polymorphisms are associated with type 2 diabetes mellitus: a meta-analysis study," Diabetes/Metabolism Research and Reviews, vol. 29, no. 7, pp. 532–545, 2013.

[111] J. Wang, J. Zhang, L. Li et al., "Association of rs12255372 in the TCF7L2 gene with type 2 diabetes mellitus: a meta-analysis," Brazilian Journal of Medical and Biological Research, vol. 46, no. 4, pp. 382–393, 2013.

[112] M. Saadat, "Null genotypes of glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms increased susceptibility to type 2 diabetes mellitus, a meta-analysis," Gene, vol. 532, no. 1, pp. 160–162, 2013.

[113] S.-T. Tang, C.-J. Wang, H.-Q. Tang, Q. Zhang, and Y. Wang, "Evaluation of glutathione S-transferase genetic variants affecting type 2 diabetes susceptibility: a meta-analysis," Gene, vol. 530, no. 2, pp. 301–308, 2013.

[114] J.-H. Zhong, A. C. Rodriguez, N.-N. Yang, and L.-Q. Li, "Methylenetetrahydrofolate reductase gene polymorphism and risk of type 2 diabetes mellitus," PLoS ONE, vol. 8, no. 9, Article ID e74521, 2013.

[115] S. Yang, J. Zhang, C. Feng, and G. Huang, "MTHFR 677 T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: a meta-analysis," Metabolism: Clinical and Experimental, vol. 62, no. 4, pp. 586–594, 2013.

[116] Y. Hua, J. Shen, Y. Song, Y. Xing, and X. Ye, "Interleukin-10 −2592C/A, −2819C/T and −21082A/G polymorphisms with risk of type 2 diabetes mellitus: a HuGE review and meta-analysis," PLoS ONE, vol. 8, no. 6, Article ID e66568, 2013.

[117] M. A.-H. Helaly, E.-S. Z. Hataha, M. Abu-Elmagd et al., "Association of IL-10 and IL-6 gene polymorphisms with type 2 diabetes mellitus among Egyptian patients," European Journal of General Medicine, vol. 10, no. 3, pp. 158–162, 2013.

[118] S. Vats, V. Sambyal, and A. J. S. Bhanwery, "Genetic links between coronary artery disease and type 2 diabetes," Human Biology Review, vol. 2, no. 2, pp. 90–119, 2013.

[119] G. Wang, Q. Zhang, N. Xu et al., "Associations between two polymorphisms (FokI and BsmI) of vitamin D receptor gene and type 1 diabetes mellitus in Asian population: a meta-analysis," PLoS ONE, vol. 9, no. 3, Article ID e89325, 2014.

[120] K. Tizaoui, W. Kaabachi, A. Hamzaoui, and K. Hamzaoui, "Contribution of VDR polymorphisms to type 1 diabetes susceptibility: systematic review of case-control studies and meta-analysis," Journal of Steroid Biochemistry and Molecular Biology, vol. 143, pp. 240–249, 2014.

[121] L. Sun, Q. Yuan, N. Cao et al., "VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: a meta-analysis," The Scientific World Journal, vol. 2014, Article ID 624573, 11 pages, 2014.

[122] B. S. Delamea, L. C. F. Pinto, C. B. Leitão, K. G. Santos, and L. H. S. Canani, "Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis," BMC Medical Genetics, vol. 15, article 9, 2014.